Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Huntington's disease

This page shows the latest Huntington's disease news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: success for Pfizer and Lilly arthritis drug, Darzalex soars, IMI launches Accelerator

Daily Brief: success for Pfizer and Lilly arthritis drug, Darzalex soars, IMI launches Accelerator

However the company’s consumer and medical devices divisions are still in the doldrums. ... researchers’time). Many of the proposed projects address brain disorders, such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, major

Latest news

More from news
Approximately 4 fully matching, plus 31 partially matching documents found.

Latest Intelligence

  • Deal Watch May 2016 Deal Watch May 2016

    Teva's drug SD 809 for the treatment of Huntington's disease was part of the acquisition of Auspex at a cost of $3.5bn. ... disease late last year, Bayer announced another gene editing pact this month with ERS Genomics.

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Voyager Therapeutics/ Sanofi (Genzyme). Gene therapy - Parkinson's disease, Friedreich's ataxia and Huntington's disease. ... Collaboration - discover, develop, commercialise. 450. Heptares Therapeutics/ Sosei Group . Novel G protein-coupled receptor

  • Deal Watch table for April 2013 Deal Watch table for April 2013

    480. Isis Pharmaceuticals/ Roche. Collaboration. To develop treatments for Huntington's disease based on Isis' antisense oligonucleotide technology.

  • Pharma deals during April 2013 Pharma deals during April 2013

    These deals, along with that announced with Moderna Therapeutics (messenger RNA therapies) and the purchase of AlphaCore (phase I programme for cardiovascular disease) earlier in the year exemplify AZ's focus ... Isis/ Roche. Isis, another biotech with a

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • uniQure appoints chief executive officer uniQure appoints chief executive officer

    This is an exciting time for uniQure, and I am fully committed to the company's success and the execution of our core strategic goals. “ ... for congestive heart failure and Huntington's disease into the clinic.”.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • VCCP Health

    Not only do they bring experience working on Rx accounts such as the immunology biosimilar portfolio for Novartis, but passion and expertise for animal health, disease awareness and charity work. ... 2016, Echoes of the past, Huntington's Disease (Teva).

  • Use of biomarkers in marketing

    pathway. When we think of biomarkers, we usually imagine the detection of genetic disorders such as Huntington’ s disease and Alzheimer’ s; these are prognosis biomarkers. ... A crowded market of biologics treating a chronic disease with very similar

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Quick links

Infographics

Multimedia